Minerva Surgical, Inc.
UTRS · OTC
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.06 | 0.02 | -0.01 | 0.01 |
| FCF Yield | -17.46% | -21.24% | -40.24% | -112.54% |
| EV / EBITDA | -13.53 | -13.24 | -3.45 | -8.95 |
| Quality | ||||
| ROIC | -9.55% | -10.91% | -14.01% | -9.13% |
| Gross Margin | 51.97% | 55.28% | 55.97% | 53.40% |
| Cash Conversion Ratio | 0.71 | 1.11 | 0.74 | 2.51 |
| Growth | ||||
| Revenue 3-Year CAGR | -0.20% | 0.34% | 11.27% | 24.87% |
| Free Cash Flow Growth | 46.87% | -13.71% | 45.79% | -129.36% |
| Safety | ||||
| Net Debt / EBITDA | -7.11 | -5.05 | -1.40 | -6.29 |
| Interest Coverage | -5.20 | -6.78 | -9.65 | -5.06 |
| Efficiency | ||||
| Inventory Turnover | 0.32 | 0.33 | 0.32 | 0.38 |
| Cash Conversion Cycle | 294.14 | 264.72 | 273.35 | 243.74 |